Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?

MRP are enrolled in the myeloid (i.e. monocyte/macrophage) inflammatory component of synovitis and their systemic levels have been shown to strongly correlate with clinical (for DAS28 r?=?0.89, p?<?0.001) and ultrasound (r?=?0.64, p?<?0.001) disease activity [31-33]. [...]higher MRP8/14 baseline levels have been associated with EULAR response to adalimumab (OR 3.14, p?=?0.04; area under the curve (AUC) 0.688), infliximab (OR 7.82, p?=?0.006; AUC 0.791) and rituximab (OR 210.21, p?=?0.002; AUC 0.984), after adjustment for baseline DAS28 and 68-joint tender joint count (the only two other... Mehr ...